VTE PREDICT - predicting risk of recurrent venous thromboembolism (VTE)
Last edited 05/2023 and last reviewed 05/2023
VTE PREDICT
- VTE PREDICT is an online calculator that assists with the decision to whether stop or continue anticoagulation for venous thromboembolism (VTE) after initial treatment
- considers individual risks of recurrence and bleeding
- study by de Winter et al aimed to develop and externally validate models for predicting 5-year risks of recurrence and bleeding in patients with VTE without cancer who completed at least 3 months of initial treatment - used to estimate individual absolute benefits and harms of extended anticoagulation
- considerations:
- anticoagulant treatment is effective in reducing VTE recurrence risk but it is associated with a 1%-2% annual risk of major bleeding
- risk of VTE recurrence is low (3% per year or less), if the VTE has been provoked by major transient risk factors (e.g. major surgery), and treatment discontinuation is recommended after 3 months
- considerations:
- concluded that
- VTE-PREDICT risk score estimates the risks of recurrent VTE and bleeding in patients with VTE who do not have active cancer and who have completed initial anticoagulant treatment
- VTE-PREDICT risk score can be applied to estimate the absolute benefits and harms of extended anticoagulation for individual patients and support shared decision-making
- considers individual risks of recurrence and bleeding
- for online VTE-PREDICT calculator - click here
Reference:
- de Winter MA et al; VTE-PREDICT study group. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. Eur Heart J. 2023 Apr 7;44(14):1231-1244. doi: 10.1093/eurheartj/ehac776. PMID: 36648242; PMCID: PMC1007939